Q Zhang, P Bastard, A Cobat, JL Casanova - Nature, 2022 - nature.com
SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases …
J Tang, C Zeng, TM Cox, C Li, YM Son, IS Cheon… - Science …, 2022 - science.org
SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in …
INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines are highly effective at preventing infection and especially severe disease …
mRNA vaccines for SARS-CoV-2 have been authorized for emergency use. Despite their efficacy in clinical trials, data on mRNA vaccine–induced immune responses are mostly …
H Qi, B Liu, X Wang, L Zhang - Nature Immunology, 2022 - nature.com
Two and a half years into the COVID-19 pandemic, we have gained many insights into the human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast- derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
Certain bacterial colonists induce a highly specific T cell response. A hallmark of this encounter is that adaptive immunity develops preemptively, in the absence of an infection …